Latest News & Features
Biotechnology
Opposition Division upholds patent challenged by 'straw men' | Dutch biotech has seen off challenges to patents in Europe and Japan. 23 April 2024
Medtech
Medtech company moved more than $1 billion in income from its US operations to a Caribbean island | New twist in long-running transfer pricing dispute between company and the IRS over ‘arm's-length’ royalty owed under intercompany licences. 18 April 2024
Biotechnology
As artificial intelligence creates a complex legal landscape for healthcare and medtech, Janine Swarbrick of HGF explores two case studies that shed light on how to claim an AI invention. 18 April 2024
Careers
Ex-head of Kramer Levin life sciences practice leaves for new firm | 20 years of experience includes numerous multi-billion dollar cases for some of the world’s best-selling drugs. 16 April 2024
Big Pharma
Judges determine six claims of Novarad’s AR patent to be unpatentable but uphold a further claim | Decision follows unsuccessful challenge by Medivis to another Novarad patent in March. 16 April 2024
Biotechnology
A US District Court has granted a motion to stay the company’s lawsuit against Pfizer and BioNTech | Decision pauses proceedings until two inter partes review proceedings are resolved. 16 April 2024
Big Pharma
Endo and its subsidiary have challenged the FDA's approval of an application by BPI Labs and Belcher Pharmaceuticals | Dispute argues the FDA undermined regulatory frameworks and patent protection. 11 April 2024
Big Pharma
Diabetes drug is known for its off-label use as a weight-loss aid | Judge censures pharma giant for using state law instead of federal law in complaint | Development follows a wave of litigation involving Mounjaro. 11 April 2024
Biotechnology
Delaware district court more convinced by Arbutus on claim construction points | Canadian biotech “pleased” with outcome in latest round of dispute over lipid nanoparticles delivery system. 9 April 2024
Big Pharma
Annual global sales of Pfizer and Astella blockbuster drug reach roughly $5 billion |
Nonprofits argue the drug is sold at a price three to six times higher in the US than it’s priced in other similar high-income countries | Move to curb drug prices follows controversial march-in rights plan. 9 April 2024